Currently, there are 173.41M common shares owned by the public and among those 171.95M shares have been available to trade.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The company’s stock has a 5-day price change of -17.21% and -17.06% over the past three months. TDOC shares are trading 3.74% year to date (YTD), with the 12-month market performance down to -37.51% lower. It has a 12-month low price of $6.76 and touched a high of $15.95 over the same period. TDOC has an average intraday trading volume of 6.98 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -20.35%, -10.52%, and -2.36% respectively.
Institutional ownership of Teladoc Health Inc (NYSE: TDOC) shares accounts for 74.03% of the company’s 173.41M shares outstanding.
It has a market capitalization of $1.64B and a beta (3y monthly) value of 1.27. The earnings-per-share (ttm) stands at -$5.88. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.85% over the week and 9.68% over the month.
Earnings per share for the fiscal year are expected to increase by 83.74%, and 3.22% over the next financial year. EPS should grow at an annualized rate of 49.56% over the next five years, compared to -33.66% over the past 5-year period.
Looking at the support for the TDOC, a number of firms have released research notes about the stock. Goldman stated their Buy rating for the stock in a research note on November 15, 2024, with the firm’s price target at $14. Jefferies coverage for the Teladoc Health Inc (TDOC) stock in a research note released on September 17, 2024 offered a Hold rating with a price target of $10. Cantor Fitzgerald was of a view on February 29, 2024 that the stock is Overweight, while Leerink Partners gave the stock Market Perform rating on February 26, 2024, issuing a price target of $17. DA Davidson on their part issued Neutral rating on January 17, 2024.
